cbdMD Earnings Call Transcripts
Fiscal Year 2026
-
Net sales rose 19% year-over-year to $5.6 million, driven by core growth and the Bluebird Botanicals acquisition. Gross margin declined to 58% due to wholesale mix and compliance costs, while strategic investments in Medicare and regulatory agility position the company for long-term growth.
-
The meeting saw all director nominees elected and all proposals, including a reverse stock split, preferred stock issuances, and the 2025 Equity Compensation Plan, approved by strong majorities. Voting was conducted online, and results will be filed with the SEC.
-
Sequential revenue growth continued with Q1 FY26 up 12% from Q4, driven by D2C and wholesale channels. Gross margin declined to 60% due to mix shift, but net loss improved significantly. Acquisition of Bluebird Botanicals and strengthened liquidity position support future growth.
Fiscal Year 2025
-
Fiscal 2025 saw improved operating results, stronger balance sheet, and margin gains, with Oasis beverage expansion and regulatory shifts offering growth potential. Regulatory changes, including a White House executive order, may drive significant new demand in 2026.
-
Q3 FY25 net sales declined 10.9% year-over-year to $4.6M, with gross margin steady at 61%. OASIS Social Tonic expanded to seven states, driving early direct-to-consumer growth, while regulatory disruptions impacted wholesale. Net loss narrowed year-to-date, and the company remains focused on margin discipline and strategic growth.
-
Q2 FY25 saw improved profitability, a strengthened balance sheet, and restored NYSE compliance after a major capital restructuring. Wholesale growth and Herbal Oasis expansion are expected to drive revenue in the second half, with liquidity sufficient through FY26.